If you have been reading about Incretin hormone and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-24. Numbers and descriptions here follow the published literature rather than marketing material.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | 39-residue synthetic peptide |
| Average molecular mass | About 4813.5 Da | Free base form |
| Appearance | White to off-white powder | Solid after lyophilization |
| Solubility class | Freely soluble in water | Also soluble in neutral aqueous buffers |
| Typical storage | At or below -20 °C, desiccated | Protect from light and moisture |
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
==== United Kingdom ==== 5-MAPB was originally banned in the UK in June 2013 under a Temporary class drug order. On March 5, 2014, the UK Home Office announced that 5-MAPB would be made a class B drug on 10 June 2014 alongside every other benzofuran entactogen and many structurally related drugs.
== Background == The album's title is taken from Heap's elliptical-shaped home in Essex, England wherein she began work on the project. The album's artwork was created using pictures from Flickr taken by fans. She composed and wrote all of the songs on the album prior to recording them in the studio, and recorded all of the vocals for the album in one month. During the making of the album, she frequently uploaded early studio mixes of its songs online in order to receive feedback from fans. In July 2009, a promotional copy of the album (designed by Andy Hau) appeared on eBay; Heap in return placed a bid of £10,000,000 to try to reclaim the album, which eBay rejected. As of 8 July, eBay had ended the auction. On 14 July, the first single "First Train Home" was released, and a digital pre-order for the album became available on iTunes in two versions. The deluxe version includes instrumental tracks of the entire album. Both standard and deluxe editions feature a "Behind the scenes" video when pre-ordered. As the song "The Fire" is already an instrumental, the "instrumental" version on the Deluxe edition's second disc consists of just the crackling fire in the background of the song proper. The solo piano track, without the fire sounds, was included only on the Deluxe CD copy of the album, as a hidden track at the end of "Half Life"; digital copies omit this hidden track. In Japan, the song "Not Now, But Soon" from the Heroes soundtrack was included as a bonus track.
Pre-formed mediators stored in granules biogenic amines (histamine, serotonin, dopamine) proteases (serine proteases including tryptase and chymase, aspartic acid proteases, cysteine proteases, metalloproteinases including CPA3) proteoglycans (heparin, chondroitin sulfate) cytokines (TNF, IL-4) growth factors (GM-CSF, bFGF, VEGF, NGF) lysosomal enzymes (β-hexosaminidase, β-glucuronidase, CD63) Newly synthesized inflammatory mediators lipid mediators (eicosanoids, thromboxane, LTB4, LTC4, PAF, PGD2) neuropeptides (CRH, VIP) growth factors (PDGF, GnRH) chemokines (MCP-1, eotaxin, TARC, RANTES) cytokines (IL-1, IL-3, IL-6, IL-18, SCF, TGF-β)
In March 2007, in the final verdict by the Supreme Court of Cassation, stated that "in the years of 1994 to 1998 there was no ascertained positive case of doping substances by Juventus players, that the purchase of erythropoietin or its administration to the athletes of the club does not emerge from any act of the trial, and that the same expert had identified the possibility of an administration of erythropoietin in distant terms from the sure evidence ("very probable" and in two cases "practically certain"): it is that therefore, the judgement of probability and not of certainty, did not allow for a statement of responsibility." The verdict also went on to say: "In response to the conclusion taken, the territorial court notes that there were no deferred values higher than the limits set in the various antidoping protocols and that the situation of the Juventus players, both with reference to the average hematological values, and in relation to that of material balance, did not differ from the national average population.
Sources: en.wikipedia.org
Ants vary in colour; most ants are yellow to red or brown to black, but a few species are green and some tropical species have a metallic lustre. More than 13,800 species are currently known (with upper estimates of the potential existence of about 22,000; see the article List of ant genera), with the greatest diversity in the tropics. Taxonomic studies continue to resolve the classification and systematics of ants. Online databases of ant species, including AntWeb and the Hymenoptera Name Server, help to keep track of the known and newly described species. The relative ease with which ants may be sampled and studied in ecosystems has made them useful as indicator species in biodiversity studies.
After 1956, 1962, and 1964; East Germany competed in the Summer Olympics as a separate member of the IOC. The 800-page Doping in Germany from 1950 to today study details how the West German government helped fund a wide-scale doping programme. West Germany encouraged and covered up a culture of doping across many sports for decades. As in 1957, when the Saarland acceded, East German sport organisations ceased to exist in late 1990 as their subdivisions and their members joined their Western counterparts. Thus, the present German organisations and teams in football, Olympics and elsewhere are identical to those that had been informally called "West German" before 1991. The only differences were a larger membership and a different name used by some foreigners. These organisations and teams in turn mostly continued the traditions of those that represented Germany before the Second World War, and even the First World War, thus providing a century-old continuity despite political changes. On the other hand, the separate East German teams and organisations were founded in the 1950s; they were an episode lasting less than four decades, yet quite successful in that time. West Germany played 43 matches at the European Championships, more than any other national team.
== Discovery and structure == Resistin was discovered in 2001 and identified as a hormone produced by adipose tissue, with a role in promoting insulin resistance. Specifically, elevated resistin levels appear to interfere with the action of insulin on adipose cells. Subsequent studies noted a link between resistin and activation of pro-inflammatory cytokines.
Sources: en.wikipedia.org
== Selectivity == While serine/threonine kinases all phosphorylate serine or threonine residues in their substrates, they select specific residues to phosphorylate on the basis of residues that flank the phosphoacceptor site, which together comprise the consensus sequence. Since the consensus sequence residues of a target substrate only make contact with several key amino acids within the catalytic cleft of the kinase (usually through hydrophobic forces and ionic bonds), a kinase is usually not specific to a single substrate, but instead can phosphorylate a whole "substrate family" which share common recognition sequences. While the catalytic domain of these kinases is highly conserved, the sequence variation that is observed in the kinome (the subset of genes in the genome that encode kinases) provides for recognition of distinct substrates. Many kinases are inhibited by a pseudosubstrate that binds to the kinase like a real substrate but lacks the amino acid to be phosphorylated. When the pseudosubstrate is removed, the kinase can perform its normal function.
=== Backbone modifications === Nucleoside organothiophosphate (PS) analogs of nucleotides give oligonucleotides some beneficial properties. Key beneficial properties that PS backbones give nucleotides are diastereomer identification of each nucleotide and the ability to easily follow reactions involving the phosphorothioate nucleotides, which is useful in oligonucleotide synthesis. PS backbone modifications to oligonucleotides protects them against unwanted degradation by enzymes. Modifying the nucleotide backbone is widely used because it can be achieved with relative ease and accuracy on most nucleotides. Fluorescent modifications on 5' and 3' end of oligonucleotides was reported to evaluate the oligonucleotides structures, dynamics and interactions with respect to environment.
However, market observers have suggested the pushback from central bankers, professional economists, and congressional Republicans may have led many investors to conclude that the investigation probably will not lead to a long-term shift in the central bank's independence. Powell could remain the Federal Reserve Chair if the United States Senate does not confirm a replacement while Powell's term as a Federal Reserve Governor does not expire until 2028, and some observers have suggested that Powell may choose to serve the entire term to help preserve the central bank's independence—like Federal Reserve Chair Marriner Eccles did after President Harry S. Truman declined to reappoint Eccles as chair in 1948 and led to the Federal Reserve's 1951 Accord with the Treasury Department. Powell has not publicly commented on whether he will do so or not. Additionally, many legal commentators reportedly expect the U.S. Supreme Court to rule against the Trump administration in the lawsuit over the attempted removal of Federal Reserve Governor Lisa Cook in light of a ruling the Court issued the previous year and the oral arguments the Court held on January 21, 2026.
== Personal life == Woolley married bacteriologist Janet Ruth McCarter in 1945. Woolley had Diabetes mellitus type 1 from childhood, and in 1923 was among the first children to receive insulin to treat the condition. He nonetheless experienced blindness as a complication of his diabetes, and was completely blind from age 25 until his death from a heart attack at age 52, while hiking in Cuzco, Peru.
Sources: en.wikipedia.org
It is a synthetic peptide and a dual agonist of two incretin receptors. It is not a small molecule, and it is not structurally related to the older single-receptor peptide agonists.
The C20 fatty diacid promotes tight binding to serum albumin. That binding reduces renal clearance and extends circulation time compared with an unmodified peptide of similar length.
It is not fully established. Studies indicate that both receptors contribute to the observed effects, but the exact split between the two signaling pathways in humans remains an open question.
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.